SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION...

31

Transcript of SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION...

Page 1: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 2: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 3: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 4: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 5: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 6: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 7: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 8: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 9: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 10: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 11: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 12: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 13: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 14: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 15: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 16: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 17: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 18: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 19: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 20: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 21: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 22: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 23: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 24: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 25: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 26: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 27: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 28: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 29: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 30: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3
Page 31: SGLT2 inhibitors and CV safety4. 25 No BENEFIT Answer 25% . WHAT IS THE % RELATIVE RISK REDUCTION WITH SGLT2 INHIBITORS FOR END STAGE RENAL DISEASE 2. 3. 4. ... 17160 10142 7020 0.3

The SGLT2 Inhibitors: Heart Failure Drugs that Also Lower Glucose · 2019-12-16 · The SGLT2 Inhibitors: Heart Failure Drugs that Also Lower Glucose Gregg C. Fonarow, MD, FACC, FAHA,

The SGLT2 Inhibitors: Heart Failure Drugs that Also Lower Glucose · 2019-12-16 · The SGLT2 Inhibitors: Heart Failure Drugs that Also Lower Glucose Gregg C. Fonarow, MD, FACC, FAHA,

SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:

SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:

SGLT2 Inhibitors: A Dynamic and Evolving Therapeutic Option · SGLT2 inhibitors are not indicated for weight loss Glucose Filtration Glomerulus SGLT2 SGLT1 Distal Tubule Collecting

SGLT2 Inhibitors: A Dynamic and Evolving Therapeutic Option · SGLT2 inhibitors are not indicated for weight loss Glucose Filtration Glomerulus SGLT2 SGLT1 Distal Tubule Collecting

Comparative Safety and Effectiveness of Type 2 …€¦ · Web viewBennett 2011 did not include sodium glucose co-transporter 2 (SGLT2) inhibitors or DPP-4 inhibitors.1 Therefore,

Comparative Safety and Effectiveness of Type 2 …€¦ · Web viewBennett 2011 did not include sodium glucose co-transporter 2 (SGLT2) inhibitors or DPP-4 inhibitors.1 Therefore,

Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the … · glucose linked transporter 2 (SGLT2) inhibitors. 1,4 According to the ADA, a patient-centered approach should

Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the … · glucose linked transporter 2 (SGLT2) inhibitors. 1,4 According to the ADA, a patient-centered approach should

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors & Kidney ...

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors & Kidney ...

Marine Safety4 Casualty

Marine Safety4 Casualty

Sodium Glucose Cotransporter · Effects of SGLT2 Inhibitors on Glycemia SGLT2 inhibitors are effective in lower-ing PG when used as monotherapy or in combination with other oral agents

Sodium Glucose Cotransporter · Effects of SGLT2 Inhibitors on Glycemia SGLT2 inhibitors are effective in lower-ing PG when used as monotherapy or in combination with other oral agents

Review Article Sodium-glucose Co-transporters-2 Inhibitors ... · Among them, sodium-glucose co-transporter 2 (SGLT2) inhibitors have emerged as a class of drug with proven robust

Review Article Sodium-glucose Co-transporters-2 Inhibitors ... · Among them, sodium-glucose co-transporter 2 (SGLT2) inhibitors have emerged as a class of drug with proven robust

What Can SGLT-2 Inhibitors Do For the Cardiovascular Patient?/media/Non-Clinical/Files-PDFs... · SGLT2 Inhibitors: Additional Thoughts • Hypoglycemia risk ⇈when an insulin secretagogue

What Can SGLT-2 Inhibitors Do For the Cardiovascular Patient?/media/Non-Clinical/Files-PDFs... · SGLT2 Inhibitors: Additional Thoughts • Hypoglycemia risk ⇈when an insulin secretagogue

Sodium-glucose Co-transporter 2 (SGLT2) I nhibitors and ......Sodium-glucose co-transporter 2 (SGLT2) inhibitors are the newest class of oral antidiabetic agents. They have a unique

Sodium-glucose Co-transporter 2 (SGLT2) I nhibitors and ......Sodium-glucose co-transporter 2 (SGLT2) inhibitors are the newest class of oral antidiabetic agents. They have a unique

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a ... · drugs, sodium-glucose co-transporter 2 (SGLT2) inhibitors, that act via this mechanism have been approved as therapy for

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a ... · drugs, sodium-glucose co-transporter 2 (SGLT2) inhibitors, that act via this mechanism have been approved as therapy for

10.1 kamlesh Barcelona PCDE SGLT2i 290416 Final · 2016-05-02 · Remaining glucose is reabsorbed by SGLT1 (10%) Proximal tubule Glucose filtration SGLT2 inhibitors inhibit SGLT2

10.1 kamlesh Barcelona PCDE SGLT2i 290416 Final · 2016-05-02 · Remaining glucose is reabsorbed by SGLT1 (10%) Proximal tubule Glucose filtration SGLT2 inhibitors inhibit SGLT2

Class Update: Sodium-glucose Cotransporter 2 (SGLT2 ... · SGLT2 inhibitors are the newest class of antidiabetic agents for patients with T2DM. SGLT2 inhibitors increase urinary glucose

Class Update: Sodium-glucose Cotransporter 2 (SGLT2 ... · SGLT2 inhibitors are the newest class of antidiabetic agents for patients with T2DM. SGLT2 inhibitors increase urinary glucose

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From … · 2016-04-18 · SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study Diabetes

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From … · 2016-04-18 · SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study Diabetes

CVOT in Diabetes: Implications for SGLT2 Inhibitors?

CVOT in Diabetes: Implications for SGLT2 Inhibitors?

Organ protection by SGLT2 inhibitors: role of metabolic ...

Organ protection by SGLT2 inhibitors: role of metabolic ...

Role of Sodium Glucose Co-Transporter 2 (SGLT2) …...Co-Transporter 2 (SGLT2) Inhibitors in Diabetes Management Manoela Braga MD Assistant Professor of Medicine Division of Endocrinology

Role of Sodium Glucose Co-Transporter 2 (SGLT2) …...Co-Transporter 2 (SGLT2) Inhibitors in Diabetes Management Manoela Braga MD Assistant Professor of Medicine Division of Endocrinology

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment ...circ.ahajournals.org/content/circulationaha/early/2016/07/28/... · glycosuric mechanism, SGLT2 inhibitors also reduce

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment ...circ.ahajournals.org/content/circulationaha/early/2016/07/28/... · glycosuric mechanism, SGLT2 inhibitors also reduce

SGLT2 inhibitors in the treatment of diabetic nephropathy

SGLT2 inhibitors in the treatment of diabetic nephropathy